2010 Westlake International Medicine Conference-
Translational Medicine
Introduction:
Following the success of "Westlake International Conference on Personalized Medicine"
in May 2009, Zhejiang California International NanoSystems Institute (ZCNI) and the
National Key Lab for Infectious Disease Diagnosis and Treatment, First Affiliated Hospital,
Zhejiang University School of Medicine will hold the "2010 Westlake International
Conference on Translational Medicine" on June 24th-26th, 2010. The conference is chaired
by Prof. Lanjuan Li, member of the Chinese Academy of Engineering, and Dr. David
DeMarini of US Environmental Protection Agency.
This Conference aims to build an exchange platform for bio-medical research and clinical
practices of translational medicine from a high and multi-perspective viewpoint regarding
the current situation and future trends of medical development both at home and abroad,
as well the role of China in the international community of translational medicine. The
conference will consist of four themes: "Environment and Health", "Biomarkers", "Stem
Cells", and "Antibody and Medicine." It will offer scientists, clinicians, medical practitioners
and specialists, students, R&D experts and patients the opportunity to meet and discuss
the latest breakthroughs and advances in the field of translational medicine.
Date:
Jun. 24th-26th, 2010
Venue: Run Run Shaw Science and Technology Museum at Yuquan Campus, Zhejiang
University, 38, Zheda Road, Hangzhou, China
Theme 1: Environment and Health
Chair: Takehiko Nohmi, PhD,
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo,
Japan
Co-Chair: Jun Yang, PhD, Professor,
Deputy Director, Zhejiang California International NanoSystems Institute (ZCNI)
Many environmental factors are known to affect human bodies and may cause various
diseases. For example, certain chemical pollutants can cause tumors; whereas air
particulate matters are associated with cardiovascular diseases. Thus, developing new
technologies and methods to detect such environmental hazardous factors, exploring the
molecular mechanisms of the effects of environmental factors on the organism have
scientific significance on the prevention and treatment of various diseases caused by
these environmental factors. The key issues and hot topics of the environmental health
research will be the main subjects of this session. A group of prominent guest speakers
will join this session, including Dr. David Demarini from U.S. Environmental Protection
Agency (EPA) and former President of the International Environmental Mutagen Society.
Theme 2: Biomarkers
Chair: Biaoyang Lin, PhD, Professor,
Principle Investigator of the System Biology Platform of ZCNI
The session on biomarkers will be dedicated to all areas of biomarker research from
cancers to infectious diseases. The conference will bring together pharmaceutical and
diagnostic companies, medical center, hospitals and academic institutions to discuss
recent biomarker discoveries using advanced proteomics and genomics technologies
including the next-generation sequencing technologies, biomarker assay development
after discovery, and clinical validations. The sessions will cover the following topics:
Biomarker discovery using advanced proteomics and genomics technologies; Biomarkers
for personalized medicine including patient selection and monitoring response to therapy
Biomarkers in translational medicine; Biomarker assay development; and Clinical
validation of biomarkers.
Theme 3: Stem Cells
Chair: Jian-an Wang, MD
Director and Chief of Cardiology, second Affiliated Hospital, Zhejiang University School of
Medicine
Co-Chair: Chunsheng Xiang, MD
Qiushi Chair Professor of Zhejiang University, Professor of National Key laboratory for
Infectious Disease Diagnosis and Treatment
Stem cells are extraordinary types of cells that have the ability to self-renew for long
periods of time and to differentiate into specialized cells under appropriate physiological or
experimental conditions. Both basic and clinical research of stem cells has recently
provided new approaches for the treatment of a number of diseases as well as
tissue/organ injuries, including cardiovascular, neurological and musculoskeletal diseases,
diabetes and hematopoietic disorders. The goals of this meeting are to present the most
current research into the cellular and molecular biology of stem cells and their clinical
applications. It will bring together key investigators at the forefront of stem cell research in
the areas of self-renewal and tissue diversification, the stem cell niche, and stem cell
therapy, to discuss the biological and clinical significance of normal and malignant stem
cell function. Topics that will be explored in this theme are the regulation of stem cell
self-renewal in normal stem cells, cellular reprogramming mechanisms, new markers for
stem cells and clinical applications of stem cells.
Theme 4: Antibody and Medicine
Chair: Zhenping Zhu, PhD, Vice President of Novartis Biologics
Co-Chair: Benjamin Hua, PhD, President of Avalon BioSciences, Adjunct Professor of
ZCNI
With the great success rate and number of blockbuster antibody drugs in the marketplace,
monoclonal antibodies have recently become a new class of medicine for treating many
diseases such as cancer, infectious diseases and inflammatory diseases. Such
phenomenon is largely due to the development of antibody humanization and fully human
antibody technologies. In this conference, new developments of antibody technologies,
clinical applications, antibody productions, as well as IP issues will be presented and
discussed.
Conference Sponsors:
--Zhejiang California International NanoSystems Institute (ZCNI)
--National Key Laboratory for Infectious Disease Diagnosis and Treatment, First Affiliated
Hospital, Zhejiang University School of Medicine
Conference Organizing Committee:
Chair:
Lanjuan Li, MD, Professor
Member, Chinese Academy of Engineering; Chair, CAST of Zhejiang Province;
Director, National Key Laboratory for Infectious Disease Diagnosis and Treatment,
First Affiliated Hospital, Zhejiang University School of Medicine
David DeMarini, PhD
Genetic Toxicologist, Scientist, US Environmental Protection Agency(EPA), Chief
Editor, “Mutation Research-Reviews in Mutation Research”
Executive Chair:
Jun Yang, PhD, Professor
Deputy Director of Zhejiang California International NanoSystems Institute (ZCNI)
Executive Members:
Biaoyang Lin, PhD, Principle Investigator of the System Biology Platform, ZCNI
Chunsheng Xiang, PhD Qiushi Chair Professor of Zhejiang University, Professor of
National Key Laboratory for Infectious Disease Diagnosis and Treatment
Benjamin Hua, PhD, CEO of Avalon BioSciences, Ltd., Adjunct Professor of ZCNI
Confirmed Speakers of the conference:
David M. DeMarini, PhD
Genetic Toxicologist, Integrated Systems Toxicology Division,
US Environmental Protection Agency, Research Triangle, North Carolina
David J. Chen, PhD
Professor, Radiation Oncology, Southwestern Medical School of Texas
Daru Lu, PhD
Institute of Genetics, College of Life Sciences, Fudan University, Shanghai, China
Frank F. Chen, PhD
Scientist, Life Science Division, Lawrence Berkeley National Laboratory, Berkeley,
California
Guoliang Yu, PhD
Chairman and CEO, Epitomics, Inc., California, USA
Hongbing Shen, PhD
School of Public Health, Nanjing Medical University, Nanjing, China
James Zhu, JD, MBA, PhD
Partner, Perkins Coie, LLC, Los Angeles, USA
Jaume Pons, PhD
Vice President and CSO, Rinat Pharmaceuticals, Pfizer, USA
Joshua M. Hare, M.D., FACC, FAHA
Louis Lemberg Professor and Founding Director, Interdisciplinary Stem Cell Institute
(ISCI), School of Medicine, University of Miami Miller
Joe Zhou, PhD
Visiting Professor, Peking University, CEO, Genor BioPharma Co. Wison Group.
Kerry Blanchard, PhD
VP, Eli Lilly China
Lanjuan Li, MD
Member, Chinese Academy of Engineering
Director, National Key Laboratory for Infectious Disease Diagnosis and Treatment,
First Affiliated Hospital, Zhejiang University School of Medicine
Larry Witte, PhD
VP, ImClone Systems, Inc., USA
Mark Sussman, PhD
Professor of Biology, Key Investigator, Heart Research Institute, San Diego State
University
Matthew Tirrell, PhD
Arnold and Barbara Silverman Professor and Chair, Department of Bioengineering,
University of California, Berkeley
Mercedes A. Walton, PhD
Chairman and Chief Executive Officer, Cryo-Cell International, Inc.
Michael Berens, PhD
Director, Cancer and Cell Biology Division,
Head, Brain Tumor Research Lab, Translational Genomics Research Institute (TGen)
Odunsi, Kunle, MD, PhD
Professor & Research Program Director, Division of Gynecologic Oncology,
Co-Leader, Tumor Immunology and Immunotherapy Program, Roswell Park Cancer
Institute
Peter Luo, PhD
Director, Vaccines and Biological Research, Merck
Sepideh Arbabi Bidgoli, PhD
Associate Prof. of Toxicology & Pharmacology, Pharmaceutical Sciences Branch,
Islamic Azad University (IAUPS)
Shuseng Zheng, MD
Member, Chinese Academy of Engineering
President, First Affiliated Hospital, Zhejiang University School of Medicine
Susan Dillion, PhD
Vice President, Global Therapeutic Area Head, J&J Pharmaceuticals R&D, USA
Takehiko Nohmi, PhD
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo,
Japan
Takashi Yagi, PhD
Environmental Genetics Laboratory, Frontier Science Innovation Center, Osaka
Prefecture University
William M. Grady. MD
Section Chief of Medicine, Gastroenterology, School of Medicine, University of
Washington Medical Center, Associate member of Fred Hutchinson Cancer
Research Center
Young R. Seo, PhD,
Associate Professor, Department of Pharmacology, School of Medicine, Kyung Hee
University, Seoul, Korea, Editor-in-Chief of Cancer Prevention Research, Associate
Editor of Molecular and Cellular Toxicology, Board Editor of Mutation Research
Yajun Guo, PhD
Director of Institute of Oncology, Second Military Medical University, Shanghai
Yuan Xu, PhD
VP, Process Development, Novartis Biologics, Switzerland
Zhenping Zhu, MD, PhD
Vice President, Novartis Biologics; Global Head, Protein Sciences and Design,
Novartis, Switzerland
Zhongchao Han, PhD
Director of National Stem Cell Engineering Research Center, China
Director of State Key Laboratory of Experimental Hematology
Conference Secretariats:
Yanyang Wang, Tel/Fax: 86-571-86971429
Susy Jin,
Tel:
86-571-86971936
Liyun Fu
Tel:
86-571-86971936
Wei Wang,
Tel:
86-571-86971897
Address: 268, Kaixuan Road, Zhejiang University, Zhejiang California International
NanoSystems Institute, Hangzhou, China, 310029
Email：
westlakeconference@zcni.org
Website： www.zcni.org/westlakeconference
Attached is the registration process and receipt.